[Clinical usefulness of circulating ECD/HER-2 measurement for breast cancer patients' management].

Background: About 15 to 20% of breast cancer cases overexpress human epidermal growth factor receptor-2 (HER-2). This overexpression is associated with poor clinical prognosis but therapeutic success of trastuzumab or lapatinib. HER-2 extracellular domain (ECD) undergoes a proteolytic cleavage and is shed into biologic fluid as a circulating antigen called ECD/HER-2, which can be detected by immunochemical assays.

Assessment of STAN S21 fetal heart monitor by medical staff.

Objective: To compare the responses of medical staff using the STAN S21 fetal heart monitor versus standard cardiotocography (CTG) to monitor abnormal fetal heart rate in labor.

Method: Questionnaires were completed by medical staff involved in a randomized controlled trial to compare STAN surveillance with traditional surveillance before the trial had finished. Respondents were questioned about their experience and confidence using the STAN system.